Advertisement

ODAC says prostate cancer patients who lack proven BRCA mutation shouldn’t get PARP inhibitor

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The FDA Oncologic Drugs Advisory Committee agreed with the agency’s forcefully stated view that Lynparza (olaparib), a PARP inhibitor, should be given only to metastatic castration-resistant prostate cancer patients whose tumors have a BRCA mutation.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Advertisement
Advertisement
Paul Goldberg
Editor & Publisher
Table of Contents
Advertisement
Advertisement

YOU MAY BE INTERESTED IN

Advertisement
Advertisement